Quectel Releases New 4G/5G, LPWA and GNSS Antennas to Help Customers Optimize Device Performance
11.7.2023 12:00:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, an IoT global solutions provider, proudly announces the launch of an exciting line-up of antennas designed to meet a wide spectrum of requirements:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230711943901/en/
Quectel releases new 4G/5G, LPWA and GNSS antennas to help customers optimize device performance (Photo: Business Wire)
- YEMN926J1A: This state-of-the-art 9-in-1 5G screw mount combo antenna is at the forefront of technology. It offers superior performance for 5G networks and is designed with a screw mount for easy installation.
- YECW000N1A: This external antenna is specifically optimized for low power wide area (LPWA) networks. It provides excellent connectivity for LPWA applications and ensures reliable and efficient communication.
- YEGT000W8A: Our advanced active global satellite navigation system (GNSS) L1 and L5 antenna, ideal for precise positioning and timing. It offers enhanced accuracy and reliability for GNSS applications.
These antennas showcase cutting-edge technology and are designed to meet the demands of today's connectivity requirements.
“We’re proud to launch these three new antennas which further add to our range of 4G/5G, LPWA and GNSS antennas,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Antennas are often overlooked during device development but it’s important to enable developers with antennas that can be optimized for their specific use cases and provide them with the performance they need to meet their application needs. These new antennas provide customers with even greater opportunities to optimize their solutions as they build a smarter world.”
The YEMN926J1A is a 9-in-1 5G screw mount combo antenna optimized for 5G and 4G networks. It includes a GNSS antenna and measures 167mm x 57mm. Both RoHS and REACH compliant, the combo antenna also is IP67 and IP69K rated which means it offers complete protection against ingress of dust and airborne particles as well as protection against water and liquids up to and including immersion in up to 1m of water. The IP69K rating also means the product can withstand washdown pressure of 80-100 bar in phases of 14-16 l/min at temperatures of up to 80°C.
The ultra-wide-band 5G/4G antenna box provides broad coverage from 600-6,000MHz while offering support for 3G and 2G networks as well at Cat-M and NB-IoT. The antenna is designed to work with various ground plane sizes or in free space for ease of integration with nine cable connections on the antenna as required and cable length options from 300mm to 5000mm, terminated with SMA connectors. The screw mount omnidirectional antenna is easy to install with maximized durability and is compatible with Quectel's RM520x series modules.
The YECW000N1A external antenna offers high efficiency with a low profile and is optimized for LPWA connections. With dimensions of 149.73mm x 49.91mm x 35.5mm, the antenna operates in the 450-470MHz, 700-960MHz and 1710-2690MHz frequency bands. The external 4G antenna covers the main LTE bands and is also compatible with 3G, 2G and LPWA bands.
RoHS compliant, the YECW000N1A has been carefully designed so it is minimally influenced by the internal environment of devices it is connected to. This enables it to deliver better efficiency, radiation and gain while providing optimized performance for customers’ products. A further advantage is that Quectel offers flexible installation options with custom cable lengths and connectors available.
Completing Quectel’s latest antenna introductions, the YEGT000W8A is an active GNSS L1 and L5 antenna that supports the 1164-1189MHz and 1559-1606MHz frequency bands. With dimensions of 65mm x 45mm, the GNSS antenna is RoHS and IP67 compliant.
The YEGT000W8A offers a choice of configurations to guarantee the most suitable polarization type and was specifically developed for 5G RAN timing. Quectel’s positioning products support single-band or multi-band operation modes to meet various high- precision positioning requirements of customers’ products. Customized connector types and cable lengths are provided according to customers’ requirements.
In addition to providing antennas, Quectel also provides comprehensive antenna design support which includes simulation, testing and manufacturing for custom antenna solutions to meet customers’ specific application needs. This support, allied to innovative antennas, helps enable customers to optimize device performance.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711943901/en/
Contact information
Media: media@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom